Highlights
1 patentProfile claimed by owner
About
Nanoparticle based delivery of p53 protein - addressing the most frequent mutation in cancer. -
AnserBio (previously ExoProTher Medical) is a biomedical start-up developing a novel approach to cancer treatment. The company targets the p53-based tumor suppression mechanism that is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. It uses proprietary cell derived nano-particles to deliver healthy p53 and restore the body's natural tumor suppression function with minimal adverse side effects.
The company is in the preclinical stage.
Identity
| Name | AnserBio |
|---|---|
| Slug | anserbio |
| Former names | ExoProTher Medical |
| Type / kind | startup |
| Crunchbase ID | exoprother-medical |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Lq8iIMKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Nesher |
| HQ address | HaTa'asiya St, Nesher, Israel |
Web & social
| Website | https://www.anser-bio.com |
|---|---|
| https://www.linkedin.com/company/27192102 | |
| https://www.facebook.com/ExoProTher |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & SubstancesNanomaterialsBiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biotechnologymedical-technologiestherapeuticsoncologycancercell-therapynanotechnology
Funding
| Total raised | $6.5M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}